“Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation” (2026) Swiss Medical Weekly, 156(1), p. 4711. doi:10.57187/4711.